nivolumab,rp3
bms,replimune
['solid tumor', 'rp3 ', 'nivolumab', 'nivo', 's270']
today, the icr/ 's prof. kevin harrington will present on a study of rp3 as a single agent and in combination with nivolumab in patients (pts) with solid tumors in the #asco22 poster session. 5th june 2022, 08:00 cdt abstract tps2705 
The Institute of Cancer Research is making the discoveries that defeat cancer. We're the UK's top academic research centre, a postgrad college, and a charity.